Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELAMI: belantamab mafodotin + mezigdomide after BCMA CAR-T or bispecifics in relapsed multiple myeloma
2025-520976-25-00Phase 2Authorised
- Sponsor
- CHU Saint-Etienne
- Start
- Apr 2026
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belantamab mafodotin and mezigdomide in multiple myeloma (MM), sponsored by CHU Saint-Etienne. Primary endpoint: Progression-free survival (PFS). Planned start Apr 2026; status: authorised.
02
Drugs
belantamab mafodotinmezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2025-520976-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520976-25-00.